Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | TYMP | P19971 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14429208 | 1.00 | PDE2A (0.49) | PDE2AHTR1ABCHETYMPADORA2A | |
| SCHEMBL14429255 | 1.00 | PDE2A (0.49) | PDE2AHTR1ABCHETYMPADORA2A | |
| SCHEMBL14429069 | 1.00 | PDE2A (0.49) | PDE2AHTR1ABCHETYMPADORA2A | |
| SCHEMBL14429229 | 1.00 | PDE2A (0.49) | PDE2AHTR1ABCHETYMPADORA2A | |
| SCHEMBL14429231 | 1.00 | PDE2A (0.49) | PDE2AHTR1ABCHETYMPADORA2A | |
| SCHEMBL14429279 | 0.90 | PDE2A (0.48) | PDE2AHTR1ABCHETYMPADORA2A | |
| SCHEMBL14429234 | 0.86 | HTR1A (0.42) | PDE2AHTR1ABCHECA1CA2 | |
| SCHEMBL14429059 | 0.82 | TYMP (0.57) | PDE2AHTR1ABCHETYMPADORA2A | |
| SCHEMBL14429061 | 0.82 | PDE2A (0.55) | PDE2AHTR1ABCHETYMPADORA2A | |
| SCHEMBL14429165 | 0.81 | PDE2A (0.55) | PDE2AHTR1ABCHETYMPADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185063-A1 | Seven-membered ring nucleosides | IDENIX PHARMACEUTICALS, INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185063-A1 | Seven-membered ring nucleosides | NSUN2, NSUN3, HAVCR2 | PDE2A 3198/4885HTR1A 3963/4885BCHE 3255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.